sinc
worldwid
outbreak
sever
acut
respiratori
syndrom
sar
novemb
june
subsequ
smaller
outbreak
occur
result
laboratori
neglig
reemerg
sarsassoci
coronaviru
sarscov
natur
reservoir
incid
bear
wit
fact
reemerg
sarscov
infect
human
real
concern
experi
guandong
outbreak
occur
decemb
januari
suggest
clinic
present
diseas
transmiss
behavior
reemerg
sarscov
strain
differ
known
sar
outbreak
occur
mandatori
serolog
survey
conduct
defin
epidemiolog
charact
outbreak
sinc
outbreak
may
happen
place
proport
popul
expos
viru
previou
outbreak
sar
reliabl
method
differenti
recent
infect
past
exposur
vital
meaning
interpret
result
investig
avid
function
affin
antibodi
measur
overal
strength
interact
antibodi
antigen
avid
virusspecif
igg
antibodi
low
primari
viral
infect
increas
time
howev
except
rule
observ
virus
report
matur
pattern
nucleocapsid
igg
antibodi
hereaft
igg
antibodi
avid
cours
period
primari
infect
discuss
potenti
applic
find
patient
materi
methodssixtyon
patient
sar
recruit
present
studi
rang
age
year
mean
sd
year
femal
patient
present
acuteonset
fever
progress
pneumonia
otherwis
unexplain
nine
patient
requir
intens
care
eventu
recov
patient
fulfil
us
center
diseas
control
prevent
criteria
sar
serolog
evid
sarscov
infect
determin
igg
antibodi
immunofluoresc
assay
describ
elsewher
fortyon
patient
seroconvert
develop
increas
antibodi
titer
total
serum
sampl
avail
patient
provid
sampl
studi
igg
antibodi
avid
measur
approach
first
step
assess
concentr
igg
antibodi
sampl
sampl
requir
dilut
test
second
step
could
identifi
basi
serialdilut
experi
sampl
od
need
dilut
provid
linear
rang
measur
avid
second
step
concentr
igg
antibodi
measur
recombin
nucleocapsid
enzym
immunoassay
elisar
iggen
accord
manufactur
instruct
briefli
sampl
dilut
concentr
mix
serum
ml
sampl
diluent
aliquot
predilut
serum
ad
antigenco
well
incub
room
temperatur
min
well
wash
time
wash
buffer
provid
igg
antibodi
conjug
horseradish
peroxidas
ad
incub
room
temperatur
min
second
wash
step
ad
substrat
color
develop
optic
densiti
measur
nm
second
step
also
base
elisar
assay
includ
ureaelut
procedur
briefli
sampl
dilut
necessari
accord
result
obtain
first
step
neat
predilut
serum
sampl
mix
sampl
diluent
describ
sampl
mixtur
ad
duplic
antigenco
well
first
incub
step
urea
ad
one
well
wherea
volum
wash
buffer
ad
well
serv
refer
basi
initi
optim
experi
use
earli
late
sampl
collect
day
fever
onset
respect
soak
step
room
temperatur
min
moll
urea
dilut
wash
buffer
found
suitabl
thu
use
present
studi
ureasoak
step
follow
wash
time
wash
buffer
provid
subsequ
conjugateaddit
colordevelop
step
conduct
accord
manufactur
protocol
antibodi
avid
index
calcul
odureaodrefer
express
percentag
sampl
collect
day
fever
onset
also
test
igm
antibodi
igm
antibodi
detect
igg
antibodi
avid
measur
could
compar
respect
demonstr
recent
infect
igm
antibodi
also
detect
elisar
assay
briefli
sampl
treat
use
rheumatoid
factor
remov
kit
chemicon
mix
sampl
diluent
final
concentr
aliquot
dilut
sampl
ad
antigenco
well
subject
incub
wash
colordevelop
step
describ
except
igm
antibodi
use
conjug
igg
antibodi
titer
pair
serum
sampl
measur
inhous
indirect
immunofluoresc
assay
describ
elsewher
done
valu
use
chang
igg
antibodi
titer
antibodi
avid
could
compar
respect
demonstr
recent
infect
resultsfor
serum
sampl
opticaldens
valu
obtain
first
step
rang
mean
sd
sampl
od
thu
requir
dilut
second
step
requir
dilut
requir
dilut
achiev
refer
od
subject
second
step
measur
antibodi
avid
figur
show
pattern
matur
igg
antibodi
avid
infect
avid
indic
low
mean
sd
rang
among
sampl
collect
day
fever
onset
increas
intermedi
level
mean
sd
rang
among
sampl
collect
day
avid
indic
high
mean
sd
rang
among
sampl
collect
day
sampl
collect
day
fever
onset
posit
igm
antibodi
determin
elisar
assay
igmposit
sampl
avid
indic
rang
median
interquartil
rang
igmneg
sampl
avid
indic
rang
median
interquartil
rang
signific
differ
avid
level
group
sampl
p
mannwhitney
u
test
togeth
sampl
avail
patient
sampl
avail
patient
sampl
avail
patient
result
patient
least
sampl
analyz
third
sampl
patient
sampl
consid
first
sampl
collect
day
mean
sd
day
fever
onset
time
span
collect
first
second
sampl
rang
day
mean
sd
day
pair
sampl
show
signific
increas
igg
antibodi
titer
determin
inhous
indirect
immunofluoresc
assay
first
second
sampl
result
could
regard
evid
recent
infect
antibodi
avid
indic
pair
sampl
analyz
show
increas
avid
index
time
chang
avid
level
pair
sampl
shown
collect
time
interv
figur
discussionour
data
show
igg
antibodi
avid
low
primari
infect
increas
time
unidirect
manner
basi
phenomenon
measur
antibodi
avid
use
resolv
certain
difficulti
may
encount
assess
sarscov
infect
first
use
differenti
primari
infect
reexposur
although
possibl
includ
patient
reexpos
present
studi
basi
experi
viral
infect
similar
pattern
antibodi
avid
matur
reason
infer
patient
reexpos
sarscov
mount
humor
memori
immun
respons
includ
product
antibodi
high
avid
within
short
period
time
second
presenc
antibodi
low
avid
could
provid
altern
evid
demonstr
primari
infect
igm
assay
result
doubt
import
given
viral
serolog
test
base
sole
determin
presenc
igm
lead
fals
conclus
igm
respons
last
short
period
time
could
miss
serum
sampl
collect
earli
late
hand
igm
persist
month
even
year
primari
infect
reappear
secondari
infect
interpret
igm
result
one
awar
igm
assay
use
present
studi
base
indirect
enzym
immunoassay
format
sensit
might
inferior
igm
captur
format
omiss
igg
antibodi
remov
step
might
decreas
assay
sensit
nevertheless
igm
assay
result
sampl
collect
day
fever
onset
support
view
low
antibodi
avid
could
valuabl
altern
marker
defin
primari
infect
particular
serum
sampl
avail
limit
term
collect
time
point
data
show
sampl
avid
index
collect
day
wherea
sampl
avid
index
collect
day
avid
indic
could
consid
repres
matur
zone
correl
avid
time
sinc
infect
less
strong
third
comparison
avid
indic
pair
sampl
indic
approach
could
provid
help
altern
use
increas
antibodi
concentr
serolog
evid
recent
infect
particularli
import
convalesc
sampl
collect
antibodi
concentr
longer
increas
case
pair
sampl
possibl
applic
measur
antibodi
avid
sarscov
infect
includ
use
techniqu
assess
humor
respons
vaccin
candid
discrimin
primari
secondari
vaccin
failur
